EU Flu Day Launched Today by MEP Dolors Montserrat With Vaccines Europe’s Support
The first annual EU Flu Day is being launched today, 14 October 2020. The campaign seeks to highlight the importance of seasonal flu vaccination, particularly during the ongoing COVID-19 pandemic, and to address challenges for sustainable increase of flu vaccine coverage rates in Europe as a critical public health measure for healthcare systems sustainability.
It is a call to action for European citizens – particularly healthcare workers and at-risk groups – to make them aware of the need to be vaccinated against flu, in order to protect themselves, those around them as well as alleviating the stress on national health care systems.
The campaign is being spearheaded by Dolors Montserrat, a leading Member of the European Parliament (EPP, Spain) and Co-Chair of the Health Working Group. Montserrat is also a former Minister of Health in Spain. The campaign is being organised with the support of Vaccines Europe.
There are several activities being planned for EU Flu Day, including:
- #EUFluDay online campaign: EU Flu Day is an opportunity for policymakers and citizens alike to set an example. Everyone is encouraged to share a message about the importance of getting the flu vaccine on social media, using the hashtag #EUFluDay. EU policy makers have already begun posting messages of support (e.g. here, here, here), and several more are expected over the course of the day.
- EU Flu Day launch webinar: MEP Montserrat is holding a webinar to mark the launch of EU Flu Day, bringing together participants from the European Commission, World Health Organisation, European Parliament, healthcare professionals and the vaccines industry. It is titled “Flu vaccination as a public health measure during COVID-19” and is taking place from 14:00-16:00 CET on 14 October 2020. Speakers will share their views on optimal approaches to increase flu vaccine uptake during COVID-19. This will include how to overcome barriers with the uptake of seasonal flu vaccines, and how to ensure early supply forecast planning, given the long lead times for vaccine production. One key proposal is to extended window for flu vaccination, in order to meet the increased demand caused by a pandemic.
“We are calling on Europeans citizens, particularly health workers and at-risk groups, to get their seasonal flu vaccination, in order to protect themselves and others, and to avoid overwhelming national healthcare systems” said MEP Montserrat. “We want to do all we can to drive action to safeguard public health from seasonal influenza, especially in a COVID-19 setting. That’s why I am calling on EU policymakers to lead by example on 14 October – and throughout the entire season. With an annual EU Flu Day, we have an opportunity to improve flu vaccine uptake rates across the EU for future seasons. Only by taking steps like this can we safeguard public health in the face of a truly unprecedented crisis.”
The importance of flu vaccination during COVID-19
Seasonal flu vaccines are an essential part of the annual public health toolkit. It is estimated that there are up to 50 million cases of seasonal flu in Europe each year, causing up to 70,000 deaths. Seasonal flu also puts a large strain on healthcare systems, for example through hospitalisations. With the dual threat of seasonal flu and COVID-19, uptake of flu vaccines will be even more vital for public health during the 2020/2021 season to prevent the overwhelming of healthcare systems.
The WHO recommends that countries should aim for 75% flu vaccine coverage rate among at-risk groups. Yet no EU country currently meets this target. In fact, the latest available data shows an average uptake level of only 41% of those aged 65 and over, with the lowest score being only 7.7%, while some Member States are above 60%.
The COVID-19 pandemic has increased public awareness of the need for each person to take steps that protect the wider community – particularly those in at-risk groups. Seasonal flu vaccines are one of the most effective ways people can protect themselves, others and healthcare systems, particularly in a COVID-19 pandemic setting. Depending on local recommendations, flu vaccination might be prioritised to at-risk groups at the start of vaccination season, however it is important to note that people - both in and outside scope of risk groups - should consider vaccination even until January and beyond as peak phase of flu can fall to February or March.
Magdalena R. De Azero, Executive Director of Vaccines Europe, said: “The vaccine industry is currently working around the clock to develop, manufacture and supply COVID-19 vaccines. While these efforts continue, manufacturers have also managed to marginally increase their flu vaccine production to cope with increased demand. These efforts should be supported with effective national flu vaccination campaigns to ensure optimal access and uptake.” She added that “flu is an annual public health threat with or without the concurrent pandemic. Therefore, EU Flu Day needs to be a springboard for action. We need to translate ideas into reality – like expanding access to flu vaccines in new healthcare settings like pharmacies, and implementing targeted vaccination campaigns to meet demands of seasonal flu vaccination administration in a COVID-19 setting. Policymakers at both EU and national level have an essential role to play in achieving this – both this year and beyond.”
Vaccines Europe is a specialised group of the European Federation of Pharmaceutical Industries and Associations (EFPIA) that represents major innovative research-based vaccine companies as well as small and medium-sized enterprises operating in Europe which account for a large share of human vaccines used worldwide.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201014005465/en/
Contact information
Media
Magdalena R. De Azero
Executive Director, Vaccines Europe
magdalena.deazero@vaccineseurope.eu
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AmTrust Financial Services and Blackstone Credit & Insurance Close Strategic Transaction and Launch Newly Formed Multinational MGA Company Named ANV Group Holdings Ltd.5.12.2025 14:00:00 EET | Press release
AmTrust Financial Services, Inc. (“AmTrust” or the “Company”), a global specialty property casualty insurer, and Blackstone Credit & Insurance (“BXCI”), today announced the closing of a strategic transaction under which AmTrust and funds managed by BXCI have partnered to spin-off certain of AmTrust’s Managing General Agencies (“MGAs”) and fee-based businesses in the U.S., United Kingdom, and Continental Europe, into ANV Group Holdings Ltd. (“ANV”), a newly formed independent company, following receipt of regulatory approvals. AmTrust and ANV have entered into a ten-year capacity agreement through which AmTrust will remain the underwriter for the existing books of business offered through the MGAs. As previously announced on September 15, 2025, the agreement includes seven AmTrust subsidiaries: ANV Specialty, Risico, Collegiate, ANV Nordic, Arc Legal, Qualis, and Abacus. These businesses provide diverse risk and insurance coverages including cyber excess and surplus (E&S), directors and
Galderma Opens up New Chapter for Sculptra ® with MDR Certification and New Expanded Indication for Body5.12.2025 08:00:00 EET | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the certification of Sculptra for body indications in the European Union (EU) following its certification under the EU Medical Device Regulation (MDR). This expands Sculptra’s current clinical use on the face, to include four new areas: gluteal area, posterior thighs, décolletage, and upper arms. Sculptra can be used across these areas to address varied treatment goals – from improving skin quality (including the improvement in cellulite appearance), to enhancing firmness, as well as lift, projection, and contouring.1-5 Sculptra’s versatility allows practitioners to meet each patient’s unique needs, delivering natural-looking, long-lasting improvements across face and body. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204988559/en/ Meeting the moment: evolving patient needs As aesthetic expectations shift, patients are seeking more holistic
Northern Escape Heli-Skiing Takes the Title of “World’s Best Heli-Ski-Operator” for the 4th Year Running5.12.2025 03:40:00 EET | Press release
Northern Escape Heli-Skiing (NEH) has been named World’s Best Heli-Ski Operator 2025 by the World Ski Awards, marking its fourth straight victory following years 2022, 2023 and 2024. This recognition places NEH amongst an elite group of ski tourism operators consistently voted best in the world by industry leaders and enthusiasts alike. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204074550/en/ A four-year run built on reliability NEH operates in British Columbia’s Skeena Mountains, where deep northern snow and vast terrain come together with small-group heli-skiing and heli snowboarding. When helicopters can’t safely fly, NEH has cat skiing readily available as a backup — an exceedingly rare offering in this industry. The operation spans over 833,571 wild acres of alpine bowls, glaciers and old-growth tree skiing. The NEH experience Guests choose from three lodge formats designed for different group styles and expectat
Helical Fusion, Developer of Next-Generation Clean Energy Through Nuclear Fusion, Completes USD 5.5M Series A Extension Round5.12.2025 02:00:00 EET | Press release
Helical Fusion Co., Ltd. (Head Office: Chuo-ku, Tokyo; CEO: Takaya Taguchi; hereafter “Helical Fusion”), which is developing a next-generation energy source using Japan’s original Helical Stellarator technology to realize commercially viable fusion power plant in the 2030s, announced the completion of its Series A Extension round, raising approximately USD 5.5 million (≈ JPY 870 million). The round included investments from “Ecrowd NEXT”, a fund designed for individual investors, as well as multiple corporate investors and individual investors. As a result, Helical Fusion’s total Series A funding, including loans, amounts to approximately USD 21 million (≈ JPY 3.2 billion), bringing the company’s cumulative fundraising—including grants and loans—to approximately USD 38 million (≈ JPY 6.0 billion). With this funding, Helical Fusion will further accelerate development under its flagship program, the Helix Program—a comprehensive roadmap to achieve the world’s first commercially viable fu
IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance5.12.2025 02:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), announced that its partner IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision oncology company, has received the clearance of an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1 clinical trial of IDE034, a potential first-in-class B7H3/PTK7 bispecific antibody-drug conjugate (ADC). IDEAYA expects to begin patient enrollment in Q1 2026, initially evaluating patients with solid tumors known to express B7H3 and PTK7, including lung, colorectal, head and neck, and ovarian/gynecological cancers. IDE034 is a bispecific B7H3/PTK7 TOP1 ADC, independently developed by Biocytogen and licensed to IDEAYA in July 2024. The IND clearance marks an important milestone for this licensed program, supporting subsequent clinical development of IDE034, while highlighting Biocytogen’s technical capabilities in bispecific ADC discovery and development. Dr. Yue
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
